Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Studies describe pharmacokinetics, interactions with renin inhibitor ACT-178882/MK-1597

April 1, 2010

Preclinical safety of oseltamivir supports clinical development in infants

April 1, 2010

Pfizer describes identification of selective 5-HT6 receptor antagonist WAY-262531

April 1, 2010

Greater blood pressure reduction seen with LCZ-696 than with valsartan in hypertension

April 1, 2010

Second-generation cholesterol absorption inhibitors discovered at Merck & Co.

March 31, 2010

Novel HIV maturation inhibitor MPI-0461359 developed at Myriad Pharmaceuticals

March 31, 2010

Promising preclinical safety profile of new tenofovir analogue CMX-157 disclosed

March 31, 2010

Favorable preclinical safety of bispecific MM-111 antibody for HER2-positive solid tumors disclosed

March 31, 2010

Single- and repeat-dose studies encourage further evaluation of ACU-4429 in AMD

March 31, 2010

Potent and selective CB1 receptor antagonist shows promise in mouse model of obesity

March 30, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...